☆ 4.6 Review

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

NPJ VACCINES (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

添加到收藏夹

Review Virology

Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval

Ebenezer Tumban

Summary: SARS-CoV-2 candidate vaccines targeting the spike protein are showing promising results in phase I/II trials, with some already granted emergency use authorization. Expectations are high for phase III trials and recommendations for post-approval phase IV studies.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM

Cong Xu et al.

Summary: The recent global health emergency caused by SARS-CoV-2 outbreak is mediated by the interaction between the SARS-CoV-2 trimeric spike glycoprotein and the human ACE2 receptor. The SARS-CoV-2 S trimer is more sensitive to ACE2 receptor compared to SARS-CoV S trimer, potentially contributing to its superior infectivity. Research findings depict the mechanism of ACE2-induced conformational transitions in S trimer structure, aiding in the development of anti-SARS-CoV-2 vaccines and therapeutics.

SCIENCE ADVANCES (2021)

添加到收藏夹

Review Immunology

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans

Alberto Cagigi et al.

Summary: In this concise review, the concepts behind mRNA vaccination, the innate and adaptive immune response generated by mRNA vaccines in different animal models and in humans, examples of viral infections where mRNA vaccines have shown to induce potent responses, and the recent SARS-CoV-2 mRNA vaccine trials in humans are summarized.

VACCINES (2021)

添加到收藏夹

Review Immunology

Nanomaterial Delivery Systems for mRNA Vaccines

Michael D. Buschmann et al.

Summary: This review highlights the recent success of mRNA vaccines in SARS-CoV-2 clinical trials, emphasizing the crucial role of lipid nanoparticles in the delivery systems and providing an analysis of the determinants of lipid nanoparticles' performance in mRNA vaccines.

VACCINES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Emanuele Andreano et al.

Summary: Human monoclonal antibodies have been identified as safe, preventive, and therapeutic tools against COVID-19. Through single-cell sorting from COVID-19 survivors, a large number of spike protein-specific memory B cells have been identified, leading to the discovery of highly effective neutralizing antibodies. The most potent monoclonal antibody, engineered to reduce risk and prolong half-life, has been shown to neutralize both the original virus and emerging variants.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler et al.

Summary: This study found that neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals require Fc effector functions for optimal protection, reducing inflammation, improving respiratory mechanics, and being associated with diminished immune signaling and tissue repair.

CELL (2021)

添加到收藏夹

Review Microbiology

The variant gambit: COVID-19's next move

Jessica A. Plante et al.

Summary: Despite the development of vaccines, COVID-19 caused by SARS-CoV-2 continues to be a global concern due to the emergence of new variants, raising worries about increased spread and potential impacts on immunity.

CELL HOST & MICROBE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Kimberly G. Blumenthal et al.

Summary: This study investigates the occurrence of acute allergic reactions to mRNA COVID-19 vaccines among healthcare employees in Massachusetts.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Infectious Diseases

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Susanne H. Hodgson et al.

Summary: The development of a vaccine for the novel coronavirus is crucial to prevent the spread of the pandemic and reduce disease mortality. The efficacy endpoint is protection against severe disease and death, but evaluating this in phase 3 clinical trials poses challenges.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

添加到收藏夹

Editorial Material Immunology

Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines

John M. Kelso

VACCINE (2021)

添加到收藏夹

Article Microbiology

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Fatima Amanat et al.

Summary: The spike protein of SARS-CoV-2 is identified as the prime target for vaccine development. Studies show that a soluble spike protein containing deleted polybasic cleavage site and K986P and V987P (PP) mutations completely protected mice from SARS-CoV-2 challenge, indicating the importance of antigen design for inducing protective immunity.

MBIO (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust

Kamala Thiagarajan

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

News Item Critical Care Medicine

Challenges in the rollout of COVID-19 vaccines worldwide

Talha Khan Burki

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Brunda Ganneru et al.

Summary: The study reports the development and evaluation of a whole virion inactivated COVID-19 vaccine, showing high antigen-binding and neutralizing antibody titers in mice, rats, and rabbits, with excellent safety profiles.

ISCIENCE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Naveenchandra Suryadevara et al.

Summary: The study found that a subset of human monoclonal antibodies derived from convalescent SARS-CoV-2 patients possess neutralizing activity, with two antibodies capable of inhibiting infection. Mechanistic studies revealed these antibodies neutralize in part by inhibiting post-attachment steps in the infection cycle.

CELL (2021)

添加到收藏夹

Article Immunology

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Carl Graham et al.

Summary: The interaction between the SARS-CoV-2 Spike receptor binding domain (RBD) and the host cell receptor ACE2 is crucial for viral entry, with RBD being the main target for neutralizing antibodies. Mutations in RBD, N-terminal domain (NTD), and S2 subunits of Spike have been found in circulating SARS-CoV-2 variants. This study isolates and characterizes monoclonal antibodies targeting different epitopes on RBD, NTD, and S2 to understand how these mutations affect antigenicity and neutralization resistance.

IMMUNITY (2021)

添加到收藏夹

Article Immunology

Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines

Kirk Hofman et al.

Summary: The COVID-19 pandemic has claimed over 2.4 million lives globally and severely impacted the economy. The race for developing a safe and effective vaccine involves government agencies and major pharmaceutical companies as frontrunners. Interdisciplinary efforts are required for the development of an effective vaccine, involving virology, protein biology, biotechnology, immunology, and pharmaceutical sciences.

IMMUNOLOGICAL INVESTIGATIONS (2021)

添加到收藏夹

News Item Medicine, General & Internal

COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough

Rita Rubin

Summary: Efficiency of COVID-19 vaccines against SARS-CoV-2 variants is still being studied.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

The dawn of mRNA vaccines: The COVID-19 case

Rein Verbeke et al.

Summary: In less than a year since the COVID-19 pandemic outbreak, mRNA vaccines have made significant progress, with two receiving emergency use authorization and one moving to phase 3 clinical testing. These mRNA vaccines represent a new class of vaccine products, encoding the SARS-CoV-2 Spike glycoprotein to deliver mRNA to cells. The review provides a detailed overview of the composition, clinical performance, and design considerations of the most advanced mRNA vaccines, highlighting new insights and areas for future research and optimization.

JOURNAL OF CONTROLLED RELEASE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

添加到收藏夹

Editorial Material Immunology

Immunity after SARS-CoV-2 infections

Prasanna Jagannathan et al.

Summary: Studies suggest that infected individuals develop robust and long-lasting T cell immunity, which has implications for immune durability and future vaccine development.

NATURE IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

COVID-19 dynamics after a national immunization program in Israel

Hagai Rossman et al.

Summary: This study analyzed data from the Israeli Ministry of Health to investigate the real-life impact of a national vaccination campaign on the dynamics of the COVID-19 pandemic. The findings revealed a significant and early decrease in COVID-19 cases and hospitalizations in individuals aged 60 years and older who were prioritized for vaccination, indicating the effectiveness of the vaccine rollout in reducing the spread of the virus.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

How SARS-CoV-2 first adapted in humans

Hyeryun Choe et al.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

William N. Voss et al.

Summary: The study found that in convalescent individuals from COVID-19, the IgG antibodies primarily target epitopes outside the receptor binding domain (RBD) in the spike glycoprotein. It also revealed a protective NTD antibody and an NTD epitope that is recurrently mutated in emerging SARS-CoV-2 variants.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Jun Zhang et al.

Summary: Substitution of aspartic acid (D) with glycine (G) at position 614 in the spike protein of SARS-CoV-2 enhances viral spread. Cryo-electron microscopy structures reveal that the G614 strain has increased infectivity compared to the D614 strain. These findings provide insights for vaccine development and understanding viral entry mechanisms.

SCIENCE (2021)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

COVID-19 Vaccines Based on Adenovirus Vectors

Mohadeseh Hasanpourghadi et al.

TRENDS IN BIOCHEMICAL SCIENCES (2021)

添加到收藏夹

Review Immunology

mRNA vaccines manufacturing: Challenges and bottlenecks

Sara Sousa Rosa et al.

Summary: mRNA vaccines are emerging as a new alternative to conventional vaccines, with their precision, safety profile, and flexible manufacturing. They have been used to combat the Covid-19 pandemic and are being studied for other diseases as well. However, challenges in manufacturing, technology platform, and cost-effective production need to be addressed to fully utilize this new vaccination technology.

VACCINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Profiles of current COVID-19 vaccines

Franz X. Heinz et al.

WIENER KLINISCHE WOCHENSCHRIFT (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Thrombosis after covid-19 vaccination These rare events must not derail vaccination efforts

Paul R. Hunter

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Genetics & Heredity

SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription

Abdulaziz Almuqrin et al.

Summary: The ChAdOx1 nCoV-19 vaccine demonstrated expected transcriptomic and proteomic profiles in cell culture, with the SARS-CoV-2 S coding transcript dominating in all cell lines and rare adenovirus gene expression in A549 cells comparatively. This study highlights the potential for future viral vaccine vector design based on detailed insights gained from advanced transcriptomic and proteomic analyses.

GENOME MEDICINE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Yasunori Watanabe et al.

Summary: Vaccine development targeting the SARS-CoV-2 virus focuses on the S glycoprotein as the principal target of the neutralizing immune response. Adenovirus-vectored vaccines have shown effective processing and assembly of viral antigens, mimicking the observed SARS-CoV-2 virus, making them a promising platform for SARS-CoV-2 vaccines.

ACS CENTRAL SCIENCE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike

Juliane Brun et al.

Summary: The study demonstrates the differences in site-specific glycosylation between virus-derived spikes, wild-type non-stabilized spikes, and recombinant engineered spike glycoproteins. Additionally, it shows that their unique cellular secretion pathways lead to distinct protein glycosylation and secretion patterns, including shedding of spike monomeric subunits for the non-stabilized wild-type spike, potentially impacting the resulting immune response and vaccine design.

ACS CENTRAL SCIENCE (2021)

添加到收藏夹

Review Chemistry, Multidisciplinary

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

Yingzhu Li et al.

Summary: The report examines a significant number of vaccine candidates for the COVID-19 pandemic that emerged last year, discussing their technological advantages and disadvantages, the use of adjuvants and delivery systems, and providing insights into their future direction.

ACS CENTRAL SCIENCE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines

Kellie D. Nance et al.

Summary: The COVID-19 mRNA vaccines have utilized the modified nucleobase N1-methylpseudouridine (m1 Psi) to enhance effectiveness, contributing to one of the most efficient vaccine development campaigns. By explaining the development and function of m1 Psi in synthetic mRNAs, this article aims to promote understanding and highlight potential opportunities for chemical innovation in the future.

ACS CENTRAL SCIENCE (2021)

添加到收藏夹

Review Immunology

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2

Aline Baldo et al.

Summary: SARS-CoV-2 is the causative agent of COVID-19, and efforts have been made to develop vaccines using various platforms, including recombinant viral vectors. As these vaccines progress, environmental risk assessments are also necessary.

VACCINES (2021)

添加到收藏夹

Review Immunology

The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines

Tasnim Hasan et al.

Summary: This systematic review summarized the global mass-vaccination efforts for COVID-19 in the first three months, showing prioritization of frontline healthcare workers and elderly in all policies but limited information on staffing, cold chain, etc. Studies indicated that vaccination led to reduced spread of the virus and severity of cases.

VACCINES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Impact of Ribosome Activity on SARS-CoV-2 LNP - Based mRNA Vaccines

Evangelos Tsiambas et al.

Summary: The outbreak of the epidemic in China has led to a global pandemic, prompting many pharmaceutical companies to develop effective vaccines to address the emergency. Virus messenger RNA vaccines encapsulated in nanoparticles, like lipid ones, are considered promising, but there is still a lack of in-depth data on their safety, effectiveness, and immune response.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Chang Liu et al.

Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Fatima Amanat et al.

Summary: After receiving the SARS-CoV-2 spike mRNA vaccine, individuals showed robust polyclonal antibody responses, with a majority of vaccine-induced antibodies lacking neutralizing activity. However, vaccine-induced RBD binding antibodies may offer substantial protection against viral variants carrying single E484K RBD mutations.

CELL (2021)

添加到收藏夹

Letter Medicine, General & Internal

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C. Wall et al.

LANCET (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

THE CASE IS GROWING FOR MIX-AND-MATCH COVID VACCINES

Dyani Lewis

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

COVID VACCINE FLOP SPOTLIGHTS MRNA DESIGN CHALLENGES

Elie Dolgin

Summary: Scientists are searching for explanations to disappointing final-stage trial results in order to guide the future development of mRNA vaccines.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Talia Kustin et al.

Summary: Breakthrough SARS-CoV-2 infections post-vaccination may be caused by B.1.1.7 or B.1.351 variants, indicating the importance of robust vaccination. Reduced vaccine effectiveness against these variants was observed in the study, highlighting the need for continued surveillance and enhanced vaccination efforts.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Ongoing global and regional adaptive evolution of SARS-CoV-2

Nash D. Rochman et al.

Summary: The evolution of SARS-CoV-2 during the COVID-19 pandemic is primarily characterized by purifying selection, with a small number of sites evolving under positive selection. Variants in the spike protein's receptor-binding domain and the nucleocapsid protein region with NLS are enriched with positively selected amino acid replacements. These replacements form a connected network of apparent epistatic interactions and are indicators of major partitions in the SARS-CoV-2 phylogeny. The global virus diversity has been steadily increasing, with distinct periods based on phylogenetic distances and key mutations.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mixing COVID-19 vaccines appears to boost immune responses

Gretchen Vogel

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

Yongfei Cai et al.

Summary: The study found that the B.1.1.7 variant has increased receptor binding affinity, while the B.1.351 variant has developed resistance to some neutralizing antibodies by reshaping antigenic surfaces on the spike protein.

SCIENCE (2021)

添加到收藏夹

Article Cell Biology

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Allison J. Greaney et al.

Summary: Vaccine-elicited antibodies have more focused neutralizing activity on the RBD of the SARS-CoV-2 spike protein, while infection-elicited antibodies have broader binding across epitopes; hence, single RBD mutations have less impact on neutralization by vaccine sera.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

添加到收藏夹

Article Virology

Future considerations for the mRNA-lipid nanoparticle vaccine platform

Botond Z. Igyarto et al.

Summary: mRNA-based LNPs are a promising new vaccine platform, but there are still many unanswered questions regarding their mechanism and potential side effects. Utilizing dendritic cell biology could help mitigate these risks.

CURRENT OPINION IN VIROLOGY (2021)

添加到收藏夹

Review Immunology

A guide to vaccinology: from basic principles to new developments

Andrew J. Pollard et al.

Summary: Immunization is vital for public health policy and there are challenges ahead for immunologists in developing new vaccines. Although immunology has not contributed significantly to vaccine development so far, a better understanding of protective immunity is urgently needed to tackle difficult-to-target pathogens.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Sergio Linares-Fernandez et al.

TRENDS IN MOLECULAR MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade

B. Coutard et al.

ANTIVIRAL RESEARCH (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao et al.

SCIENCE (2020)

添加到收藏夹

Review Immunology

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines

Lynda Coughlan

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Tiffany Tang et al.

ANTIVIRAL RESEARCH (2020)

添加到收藏夹

Review Immunology

Recent advances in mRNA vaccine technology

Norbert Pardi et al.

CURRENT OPINION IN IMMUNOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes et al.

CELL (2020)

添加到收藏夹

Article Immunology

Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection

Katherine M. Eichinger et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Impact of mRNA chemistry and manufacturing process on innate immune activation

Jennifer Nelson et al.

SCIENCE ADVANCES (2020)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

添加到收藏夹

Article Microbiology

Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor

Peng Zhao et al.

CELL HOST & MICROBE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Neeltje van Doremalen et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Distinct conformational states of SARS-CoV-2 spike protein

Yongfei Cai et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein

Xiaoyi Fan et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

COVID-19 vaccine trials should seek worthwhile efficacy

Philip Krause et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Zunlong Ke et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

M. Alejandra Tortorici et al.

SCIENCE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET

Chuang Liu et al.

STRUCTURE (2020)

添加到收藏夹

Review Immunology

The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens

Liangwei Duan et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Immunology

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Rinke Bos et al.

NPJ VACCINES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway

Sourish Ghosh et al.

CELL (2020)

添加到收藏夹

Article Medicine, Research & Experimental

The Effect of Residual Triton X-100 on Structural Stability and Infection Activity of Adenovirus Particles

Jinhu Ma et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Chinese vaccines may need changes to improve efficacy, admits official

Owen Dyer

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Review Immunology

Adjuvants for Coronavirus Vaccines

Zhihui Liang et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Li Liu et al.

JCI INSIGHT (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

mRNA vaccines - a new era in vaccinology

Norbert Pardi et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification

Sriram Vaidyanathan et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

RNA Sensors of the Innate Immune System and Their Detection of Pathogens

Nanhua Chen et al.

IUBMB LIFE (2017)

添加到收藏夹

Article Immunology

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Naif Khalaf Alharbi et al.

VACCINE (2017)

添加到收藏夹

Article Immunology

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Johannes Lutz et al.

NPJ VACCINES (2017)

添加到收藏夹

Article Immunology

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

Aleksandra Kowalczyk et al.

VACCINE (2016)

添加到收藏夹

Article Chemistry, Multidisciplinary

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

Norbert Pardi et al.

JOURNAL OF CONTROLLED RELEASE (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

Andreas Thess et al.

MOLECULAR THERAPY (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Pre-existing immunity against Ad vectors Humoral, cellular, and innate response, what's important?

Hugues Fausther-Bovendo et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)

添加到收藏夹

Review Immunology

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials

Stefania Capone et al.

EXPERT REVIEW OF VACCINES (2013)

添加到收藏夹

Review Immunology

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

Iris Delrue et al.

EXPERT REVIEW OF VACCINES (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen

Jenny M. Reimer et al.

PLOS ONE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

Matthew D. J. Dicks et al.

PLOS ONE (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Quantitative Analysis of the Leaky Expression of Adenovirus Genes in Cells Transduced with a Replication-Incompetent Adenovirus Vector

Kahori Shimizu et al.

MOLECULAR PHARMACEUTICS (2011)

添加到收藏夹

Article Immunology

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Dan H. Barouch et al.

VACCINE (2011)

添加到收藏夹

Review Biotechnology & Applied Microbiology

New Insights on Adenovirus as Vaccine Vectors

Marcio O. Lasaro et al.

MOLECULAR THERAPY (2009)

添加到收藏夹

Article Hematology

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells:: implications for their use as vaccines

Nia Tatsis et al.

BLOOD (2007)

添加到收藏夹

Article Virology

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

Kimberly McCoy et al.

JOURNAL OF VIROLOGY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.